Meet our Principal Investigators

Beth Safirstein, M.D.

Beth Safirstein, M.D. is the Co-President of MD Clinical, a leading research center in South Florida that specializes in clinical trials for Phase 1-4 and diseases of the central nervous system. Dr. Safirstein is a board-certified Neurologist and Principal Investigator for trials involving patients with neuropsychiatric disorders and internal medicine disease. She has been a Principal Investigator since 2000.

In addition to her clinical investigatory work, Dr. Safirstein has served on review and advisory boards for Jackson Memorial Hospital, Forest Laboratories, GlaxoSmithKline, and the University of Miami’s Department of Neurology. She is an accomplished academic physician with published works in Neurology, Alzheimer Disease & Associated Disorders, and Stroke, in addition to being the recipient of several awards for the outstanding quality of her clinical and classroom performance. Cumulatively, all of this has earned Dr. Safirstein a place on the prestigious Strathmore’s WHO’S WHO list every year since 2000

Dr. Safirstein earned her doctorate at Indiana University School of Medicine and completed her residency at the University of Miami (Fla.) School of Medicine where she was the Administrative Chief Resident in Neurology. While Administrative Chief Resident in Neurology at the University of Miami, she was recognized for her outstanding work conducted through an educational grant by the American Academy of Neurology (AAN) and received the George Paff teaching award from the University of Miami, School of Medicine. She received her certification in Neurology in 2001 from the American Board of Psychiatry and Neurology and went on to earn a certification in Investigator Training for Medical Research from the University of Rochester School of Medicine in 2002 and the Atlanta School of Sleep Medicine and Technology in 2005.

Dr. Safirstein is a member of the American Academy of Sleep Medicine, the American Academy of Neurology, the Association of Clinical Research Professionals, and the Drug Industry Association.

Kerri Wilks, MD, CPI

Kerri Wilks, M.D. is the Co-President of MD Clinical, a leading research center in South Florida that specializes in clinical trials for Phase 1-4 and diseases of the central nervous system. Dr. Wilks is a board-certified Neurologist and Certified Principal Investigator for trials involving patients with neuropsychiatric disorders and internal medicine disease. She has been a Principal Investigator since 1991.

In addition to her clinical investigatory work, Dr. Wilks has served on review and advisory boards for a variety of major pharmaceutical companies. She is an accomplished academic physician and educator directing the Medical Student Clinical Clerkship for training in Neurology while at Dartmouth in 1992-1997 and was asked to serve as the Farewell Speaker for the 1996 Dartmouth Medical School Graduating Class. Cumulatively, all of this has earned Dr. Wilks a place on the prestigious Strathmore’s WHO’S WHO list.

Dr. Wilks earned her doctorate at New York Medical College and completed her residency at Albert Einstein College of Medicine where she was the Administrative Chief Resident in Neurology. Based on her dedication to clinical excellence she was appointed an Associate Professor in the Department of Neurology and the Department of Psychiatry at the Dartmouth-Hitchcock Medical Center and Dartmouth Medical School. She earned her certification in Neurology in 1992 from the American Board of Psychiatry and Neurology and served as a Diplomate to the National Board of Medical Examiners. Since then, Dr. Wilks has further earned a certification as a Certified Principal Investigator (CPI) through the APPI in 2003 and the Atlanta School of Sleep Medicine and Technology in 2006.

Dr. Wilks is a member of the American Medicine Association, the American Academy of Neurology, the Association of Clinical Research Professionals, the Academy of Pharmaceutical Physicians and Investigators, and the American Society for Clinical Pharmacology and Therapeutics.